Champions Oncology, Inc. (CSBR) News
Follow Champions Oncology, Inc. (CSBR) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 11 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
CHAMPIONS ONCOLOGY, INC. 1Q 2027: Revenue $15.23M, EPS $(0.03) — 10-Q Summary
Champions Oncology, Inc. reported results for the first quarter ended July 31, 2026, with revenue of $15.23M, an 8.8% increase from the year—ago quarter, and a net loss of $0.43M, essentially flat on a per—share basis wi
EARNINGS | Sep 11, 2026, 07:03 PM UTC
M
CSBR revenue rises 8.8% to $15.2 million
Revenue rose 8.8% year over year to $15.2 million. Oncology services margin improved to 51%, adjusted EBITDA was $671,000 and net loss narrowed to $426,000.
EARNINGS | Sep 10, 2026, 08:55 PM UTC
L
Champions Oncology reports $15.2 million revenue
Sep 10 (Reuters) - Champions Oncology Q1 revenue USD 15.2 million.
EARNINGS | Sep 10, 2026, 08:01 PM UTC
L
Champions Oncology to report Q1 results on Sept. 10, 2026
Champions Oncology (CSBR) will report financial and operational results for the quarter ended July 31, 2026 on Thursday, September 10, 2026.
EARNINGS | Sep 04, 2026, 03:15 PM UTC
L
CSBR to announce Q1 financial results on Sept. 10, 2026
Champions Oncology (CSBR) plans to announce first quarter financial results on Thursday, September 10, 2026.
EARNINGS | Sep 04, 2026, 03:15 PM UTC
L
Champions Oncology expands integrated radiopharmaceutical development with in-house SPECT/CT imaging
Champions Oncology said new molecular imaging capabilities link longitudinal radiopharmaceutical uptake to biodistribution, efficacy and clinically annotated PDX tumor biology within a single, U.S.-based workflow.
EQUITY | Sep 01, 2026, 01:02 PM UTC
L
CSBR - Champions Oncology Expands Integrated Radiopharmaceutical Development Platform with In-House SPECT/CT Imaging
CSBR - Champions Oncology Expands Integrated Radiopharmaceutical Development Platform with In-House SPECT/CT Imaging
EQUITY | Sep 01, 2026, 01:01 PM UTC
L
Champions Oncology reports Q4 adjusted EPS 1c vs. (8c) last year
Reports Q4 revenue $13.8M...
EQUITY | Jul 27, 2026, 08:40 PM UTC
L
OPK +17%, CSBR +8.2%, HAPN +7.1%, AMKR +4.4%, CDNS +3.8%, WELL +3.5%, APLD +3.1%, FFIV +1.7% after results
OPK +17%, CSBR +8.2%, HAPN +7.1%, AMKR +4.4%, CDNS +3.8%, WELL +3.5%, APLD +3.1%, FFIV +1.7% after results
EQUITY | Jul 27, 2026, 08:21 PM UTC
L
CSBR +11.8%, HAPN +7.2%, RMBS +1.7%, AGS +1.7%, FFIV +1.3%, CDNS +0.7% after results
CSBR +11.8%, HAPN +7.2%, RMBS +1.7%, AGS +1.7%, FFIV +1.3%, CDNS +0.7% after results
EQUITY | Jul 27, 2026, 08:09 PM UTC
L
CSBR Champions Oncology RESULTS: Q4, Q4 ADJ EPS $0.01, Q4 EPS $-0.05, Q4 REV $13.8M
CSBR Champions Oncology RESULTS: Q4, Q4 ADJ EPS $0.01, Q4 EPS $-0.05, Q4 REV $13.8M
EARNINGS | Jul 27, 2026, 08:00 PM UTC